Kyle Lahucik News Today

Join Novo Nordisk, Scientific American, The Cancer Research Institute, Sofinnova, Members of the Media and More Than 1,300 Investors Helping to Drive Biotech Innovation, Digital Medicine and Global Collaboration at Biotech Showcase™Registration and Partnering Platform Access Now AvailableSAN FRANCISCO--(BUSINESS WIR...

The rise of new products in California doesn’t bode well for the FDA’s forthcoming rule, set to be finalized later this year.

Pfizer picks from Roche's executive team, snagging pharma early R&D leader William Pao as the Big Pharma's next chief development officer. Leo Pharma poaches from ... a Danish meme stock for its new CEO, who will lead a reorganization of the dermatology biopharma. And Sio Gene Therapies CEO Cheruvu is out the door as Parkinson's program also hits the exit.

Former FDA head Stephen Hahn is adding a new title to his role at Flagship Pioneering: CEO of the incubator's blood cancer test startup Harbinger Health. Takeda's oncology leader Rachael Brake heads to Corbus as chief scientific officer charged with redefining scope of early-stage pipeline. Goldfinch Bio snags 13-year Ardelyx vet as CSO.

GlaxoSmithKline poached Pfizer's RNA and viral vaccines leader Phil Dormitzer, M.D., Ph.D., to shore up its vaccine business as it's lost many research staffers this past year. Parthenon Therapeutics snagged Johnson & Johnson's global head of cell therapy platform and discovery, Tamas Oravecz, Ph.D. And Rafael parted ways with five execs and reinstalled telecom tycoon Howard Jonas as CEO.

Athira Pharma's CEO resigns after investigation confirms she altered research during graduate school. vTv Therapeutics named healthcare investor Deepa Prasad its new CEO and president. Opus Genetics snagged a new chief scientific officer and chief operating officer.

Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., will retire at the end of the year, following the lead of CEO Alex Gorsky, who also departs soon. Emile Nuwaysir led Bayer's $1 billion bet on Parkinson's disease, and now he heads up gene therapy biotech Ensoma. Genentech's early cancer research leader Shiva Malek jumps to Novartis' NIBR oncology unit.

Pfizer's chief development officer, Rod MacKenzie, is the Big Pharma's second executive to retire in early 2022. NIH Director Francis Collins will also hit the exit, before the end of this year. Sanofi poaches Gilead cancer executive Valeria Fantin to run its oncology research.

FDA's vaccines office is now headed by Peter Marks after the agency's top two vaccine officials questioned the need for booster doses last month as they head toward the exit later this fall. Houston biotech incubator Sporos Biosciences snagged ex-Ovid Therapeutics Chief Medical Officer Amit Rakhit as its new CEO. In spinning off its gene therapy unit, Amicus' CEO will head to the new company being launched via a SPAC.